Exabis Library
Welcome to the e-CCO Library!
P709: Endoscopic healing and clinical remission after administration of adalimumab to patients with Crohn's disease of the small intestine
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P709: inflammatory bowel disease and colorectal cancer: analysis of a single center retrospective chart review
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P709: Is there a difference in adalimumab drug levels according to pen vs. syringe use: An international, multi-centre retrospective analysis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P710 The influence of probiotics to the efficacy of 5-ASA for the patients of ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P710: Changes of gut microbiome after anti-TNF-α therapy and the prediction of clinical remission in patients with active ulcerative colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P710: Efficacy of therapeutic intervention for ulcerative colitis patients with the Mayo Endoscopic Score of 1
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P710: Evaluation of helminth extracellular vesicles as a novel therapeutic for inflammatory bowel disease in murine models of colitis
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P710: The use of first-line biologics in patients with Crohn’s disease in Norway from 2011 to 2016
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P710: Vitamin D deficiency is not associated with depression in IBD patients
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P711 Carriage of the HLA-DQA1*05 allele is associated with a high risk of loss of response to adalimumab in patients with Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P711: A pilot study using point of care testing for infliximab and faecal calprotectin in IBD patients with a secondary loss of response
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P711: Decreased steroid exposure and disease-related hospitalizations in patients with newly diagnosed inflammatory bowel disease in the era of newer biologic agents – A multi-centre experience in Singapore.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P711: Stool microbiome communities predict remission in pediatric Crohn’s disease patients even after start of treatment
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P711: The real-life experience of vedolizumab therapy in the OBSERV-IBD cohort: a 3-year prospective observational multi-centre cohort study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P711: Vegetarian or gluten-free diet in patients with IBD – associated with lower psychological well-being and quality of life but no indication of beneficial effects on course of disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P712 Association of histologic-endoscopic mucosal healing after ustekinumab induction or maintenance therapy with 2-year outcomes in the UNIFI Phase 3 study in ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P712: Establishing pharmacokinetic equivalence between adalimumab and ABP 501 in the presence of anti-drug antibodies using population PK modelling
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P712: Fungal microbiota composition in Inflammatory Bowel Disease patients in a Norwegian cohort: characterization of disease phenotypes and correlation with clinical activity and disease course.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P712: Real-World Efficacy And Safety Of Ustekinumab And Adalimumab In Patients With Crohn's Disease: Propensity Matched Analysis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P712: Risk factors for the development of fistulae and stenoses in Crohn's disease patients in the Swiss IBD cohort
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM